Chinese Kexing COVID-19 Vaccines Can be Stored in Refrigerators

Chinese Kexing COVID-19 Vaccines Can be Stored in Refrigerators. According to reports, the coronavirus vaccine and four other experimental vaccines developed in China are currently undergoing late-stage trials to determine their effectiveness in preventing new coronavirus pneumonia.

According to preliminary test results, the vaccine developed by China Kexing triggered a rapid immune response. The study was published in a peer-reviewed paper in the medical journal “The Lancet Infectious Diseases”. One of the authors of the paper, Fengcai Zhu, said: “Our results show that Kexing vaccine can be injected with two doses 14 days apart. , To induce a rapid antibody response after four weeks of immunization.”

Zhu Fengcai said in a statement issued with the paper: “We believe that this makes the vaccine suitable for emergency use during the COVID-19 pandemic.” Kexing vaccine is currently undergoing phase three trials in Indonesia, Brazil and Turkey, and the final results will be in Released after the third phase of the trial.

According to reports, compared with the vaccines of American drugmakers Pfizer and Moderna, the Kexing vaccine can be stored in a refrigerator at room temperature of 2 to 8 degrees Celsius, and may remain stable for up to three years. The Pfizer vaccine must be stored and transported at a temperature of minus 70 degrees Celsius, while the vaccine from Moderna of the United States is expected to be stored stably at normal refrigerator temperature for 30 days, but if it is to be stored for more than 6 months, it needs to be stored at minus 20 degrees Celsius. Store at the same temperature.

Compared with the two mRNA vaccines in the United States that require an ultra-low temperature storage environment, the COVID-19 inactivated vaccine of China Kexing Company is suitable for most of the world’s third world countries that cannot provide ultra-low temperature storage.

According to peer-reviewed papers, the other two vaccines in China’s COVID-19 vaccine emergency plan (both developed by relevant research institutes of Sinopharm Group) and another vaccine from China Kexing Company have also been proven safe in early and mid-term trials. And can trigger an immune response. Brazil and Indonesia are currently considering vaccinating China’s new coronavirus vaccine in the coming months.

Ricardo Palacios, manager of the Basilbutan Relic Institute, who is conducting the third phase of the Kexing vaccination experiment in Brazil, said: “Compared with other vaccines under development, the excellent safety of China Kexing vaccine makes it more acceptable to the population. “